nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—MAOB—Zonisamide—epilepsy syndrome	0.298	0.56	CbGbCtD
Linezolid—MAOA—Zonisamide—epilepsy syndrome	0.235	0.44	CbGbCtD
Linezolid—MAOA—locus ceruleus—epilepsy syndrome	0.0132	0.241	CbGeAlD
Linezolid—MAOB—ganglion—epilepsy syndrome	0.00456	0.0832	CbGeAlD
Linezolid—MAOA—ganglion—epilepsy syndrome	0.00389	0.071	CbGeAlD
Linezolid—MAOB—hindbrain—epilepsy syndrome	0.00346	0.0631	CbGeAlD
Linezolid—MAOA—hindbrain—epilepsy syndrome	0.00295	0.0538	CbGeAlD
Linezolid—MAOB—brainstem—epilepsy syndrome	0.00198	0.0362	CbGeAlD
Linezolid—MAOB—forebrain—epilepsy syndrome	0.00191	0.0349	CbGeAlD
Linezolid—MAOB—telencephalon—epilepsy syndrome	0.00176	0.0321	CbGeAlD
Linezolid—MAOA—brainstem—epilepsy syndrome	0.00169	0.0309	CbGeAlD
Linezolid—MAOA—forebrain—epilepsy syndrome	0.00163	0.0298	CbGeAlD
Linezolid—MAOA—telencephalon—epilepsy syndrome	0.0015	0.0274	CbGeAlD
Linezolid—Rivaroxaban—ABCB1—epilepsy syndrome	0.00143	1	CrCbGaD
Linezolid—MAOB—medulla oblongata—epilepsy syndrome	0.00138	0.0252	CbGeAlD
Linezolid—MAOB—midbrain—epilepsy syndrome	0.00126	0.0231	CbGeAlD
Linezolid—MAOB—spinal cord—epilepsy syndrome	0.00123	0.0225	CbGeAlD
Linezolid—MAOA—medulla oblongata—epilepsy syndrome	0.00118	0.0215	CbGeAlD
Linezolid—MAOB—head—epilepsy syndrome	0.00109	0.02	CbGeAlD
Linezolid—MAOA—midbrain—epilepsy syndrome	0.00108	0.0197	CbGeAlD
Linezolid—MAOA—spinal cord—epilepsy syndrome	0.00105	0.0192	CbGeAlD
Linezolid—MAOB—nervous system—epilepsy syndrome	0.00104	0.019	CbGeAlD
Linezolid—MAOB—central nervous system—epilepsy syndrome	0.000999	0.0182	CbGeAlD
Linezolid—MAOB—cerebellum—epilepsy syndrome	0.000977	0.0178	CbGeAlD
Linezolid—MAOA—head—epilepsy syndrome	0.000934	0.0171	CbGeAlD
Linezolid—MAOA—nervous system—epilepsy syndrome	0.000886	0.0162	CbGeAlD
Linezolid—MAOA—central nervous system—epilepsy syndrome	0.000853	0.0156	CbGeAlD
Linezolid—MAOA—cerebellum—epilepsy syndrome	0.000833	0.0152	CbGeAlD
Linezolid—MAOB—brain—epilepsy syndrome	0.000793	0.0145	CbGeAlD
Linezolid—MAOA—brain—epilepsy syndrome	0.000677	0.0124	CbGeAlD
Linezolid—MAOA—Neuronal System—KCNAB2—epilepsy syndrome	0.000445	0.00471	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCND2—epilepsy syndrome	0.000445	0.00471	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CACNB4—epilepsy syndrome	0.00044	0.00466	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CACNA2D2—epilepsy syndrome	0.00044	0.00466	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GABRG2—epilepsy syndrome	0.00042	0.00445	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—RET—epilepsy syndrome	0.000417	0.00442	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNK3—epilepsy syndrome	0.000407	0.00431	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIK5—epilepsy syndrome	0.000407	0.00431	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNK9—epilepsy syndrome	0.000407	0.00431	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CACNG3—epilepsy syndrome	0.000407	0.00431	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP2C19—epilepsy syndrome	0.000407	0.00431	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—MAP2—epilepsy syndrome	0.000407	0.00431	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP11A1—epilepsy syndrome	0.000404	0.00428	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—FOS—epilepsy syndrome	0.000385	0.00407	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—SRC—epilepsy syndrome	0.000384	0.00407	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNV1—epilepsy syndrome	0.000378	0.00401	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—HCN1—epilepsy syndrome	0.000378	0.00401	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CACNG2—epilepsy syndrome	0.000378	0.00401	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—SSTR1—epilepsy syndrome	0.000372	0.00394	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—GABRA1—epilepsy syndrome	0.000372	0.00394	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP2D6—epilepsy syndrome	0.000365	0.00386	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—SSTR2—epilepsy syndrome	0.000358	0.00379	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CHRNA2—epilepsy syndrome	0.000356	0.00377	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNQ2—epilepsy syndrome	0.000356	0.00377	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNQ3—epilepsy syndrome	0.000356	0.00377	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—NSF—epilepsy syndrome	0.000352	0.00373	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SYN1—epilepsy syndrome	0.000352	0.00373	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CHRNA7—epilepsy syndrome	0.000346	0.00366	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—CYP2C19—epilepsy syndrome	0.000344	0.00365	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—CYP11A1—epilepsy syndrome	0.000342	0.00362	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—STXBP1—epilepsy syndrome	0.000342	0.00362	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CACNA2D2—epilepsy syndrome	0.000337	0.00357	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CACNB4—epilepsy syndrome	0.000337	0.00357	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNB1—epilepsy syndrome	0.000337	0.00357	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC1A1—epilepsy syndrome	0.000333	0.00353	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GABRG2—epilepsy syndrome	0.000322	0.00341	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNH1—epilepsy syndrome	0.000322	0.00341	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GABRA5—epilepsy syndrome	0.000318	0.00337	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—KCNJ10—epilepsy syndrome	0.000318	0.00337	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CACNA1A—epilepsy syndrome	0.000318	0.00337	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIA4—epilepsy syndrome	0.000318	0.00337	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—ABAT—epilepsy syndrome	0.000318	0.00337	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—CYP2D6—epilepsy syndrome	0.000309	0.00327	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC17A7—epilepsy syndrome	0.000305	0.00323	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GABRA1—epilepsy syndrome	0.000305	0.00323	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—ARHGEF9—epilepsy syndrome	0.000305	0.00323	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GABRB3—epilepsy syndrome	0.000305	0.00323	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GLUL—epilepsy syndrome	0.000299	0.00317	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—SLC1A3—epilepsy syndrome	0.000294	0.00311	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—AQP4—epilepsy syndrome	0.000294	0.00311	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIA2—epilepsy syndrome	0.000294	0.00311	CbGpPWpGaD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—POMC—epilepsy syndrome	0.000285	0.00302	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC1A2—epilepsy syndrome	0.000284	0.003	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIK1—epilepsy syndrome	0.000284	0.003	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CHRNA7—epilepsy syndrome	0.000284	0.003	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CHRM2—epilepsy syndrome	0.000277	0.00293	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GABRB2—epilepsy syndrome	0.00027	0.00286	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SYN1—epilepsy syndrome	0.00027	0.00285	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—NSF—epilepsy syndrome	0.00027	0.00285	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GAD2—epilepsy syndrome	0.000267	0.00282	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—STXBP1—epilepsy syndrome	0.000262	0.00278	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC1A1—epilepsy syndrome	0.000255	0.00271	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CHRNB2—epilepsy syndrome	0.000248	0.00263	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CACNA1A—epilepsy syndrome	0.000244	0.00258	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIA4—epilepsy syndrome	0.000244	0.00258	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GABRA5—epilepsy syndrome	0.000244	0.00258	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—ABAT—epilepsy syndrome	0.000244	0.00258	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNJ10—epilepsy syndrome	0.000244	0.00258	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC1A3—epilepsy syndrome	0.000241	0.00255	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIK2—epilepsy syndrome	0.000241	0.00255	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CA13—epilepsy syndrome	0.000236	0.00249	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—ARHGEF9—epilepsy syndrome	0.000234	0.00247	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GABRB3—epilepsy syndrome	0.000234	0.00247	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GABRA1—epilepsy syndrome	0.000234	0.00247	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC17A7—epilepsy syndrome	0.000234	0.00247	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GAD1—epilepsy syndrome	0.000231	0.00245	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GLUL—epilepsy syndrome	0.000229	0.00243	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CHRNA4—epilepsy syndrome	0.000225	0.00239	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIA2—epilepsy syndrome	0.000225	0.00238	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GABBR1—epilepsy syndrome	0.00022	0.00234	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC1A2—epilepsy syndrome	0.000217	0.0023	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIK1—epilepsy syndrome	0.000217	0.0023	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CHRNA7—epilepsy syndrome	0.000217	0.0023	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—CYP2C19—epilepsy syndrome	0.000216	0.00229	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIA1—epilepsy syndrome	0.000215	0.00228	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIN2A—epilepsy syndrome	0.000215	0.00228	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC6A1—epilepsy syndrome	0.000215	0.00228	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—CYP11A1—epilepsy syndrome	0.000215	0.00227	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—SLC6A4—epilepsy syndrome	0.00021	0.00222	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GABRB2—epilepsy syndrome	0.000207	0.0022	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GAD2—epilepsy syndrome	0.000204	0.00216	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—NTRK2—epilepsy syndrome	0.000204	0.00216	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—SST—epilepsy syndrome	0.000204	0.00216	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CHRNB2—epilepsy syndrome	0.000203	0.00216	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL1RN—epilepsy syndrome	0.000203	0.00215	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—CYP2D6—epilepsy syndrome	0.000194	0.00205	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNMA1—epilepsy syndrome	0.000194	0.00205	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TH—epilepsy syndrome	0.000187	0.00198	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—CHRNA4—epilepsy syndrome	0.000185	0.00196	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC1A3—epilepsy syndrome	0.000185	0.00196	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIK2—epilepsy syndrome	0.000185	0.00196	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—KCNJ11—epilepsy syndrome	0.000185	0.00196	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—POMC—epilepsy syndrome	0.000179	0.00189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CERS1—epilepsy syndrome	0.000179	0.00189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PDXK—epilepsy syndrome	0.000179	0.00189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—FAR1—epilepsy syndrome	0.000179	0.00189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—L2HGDH—epilepsy syndrome	0.000179	0.00189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ADK—epilepsy syndrome	0.000179	0.00189	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GLUD1—epilepsy syndrome	0.000179	0.00189	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GAD1—epilepsy syndrome	0.000177	0.00188	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GABBR1—epilepsy syndrome	0.000169	0.00179	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC6A1—epilepsy syndrome	0.000165	0.00174	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIN2A—epilepsy syndrome	0.000165	0.00174	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIA1—epilepsy syndrome	0.000165	0.00174	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NHLRC1—epilepsy syndrome	0.000163	0.00173	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GAMT—epilepsy syndrome	0.000163	0.00173	CbGpPWpGaD
Linezolid—MAOB—Metabolism—EPM2A—epilepsy syndrome	0.000163	0.00173	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PNPO—epilepsy syndrome	0.000163	0.00173	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—BCHE—epilepsy syndrome	0.000163	0.00172	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—DLG4—epilepsy syndrome	0.000159	0.00168	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CHRNB2—epilepsy syndrome	0.000156	0.00165	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIN2B—epilepsy syndrome	0.000155	0.00165	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—AVP—epilepsy syndrome	0.000154	0.00164	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—PLCB1—epilepsy syndrome	0.000154	0.00163	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—BDNF—epilepsy syndrome	0.000152	0.00161	CbGpPWpGaD
Linezolid—MAOB—Metabolism—QDPR—epilepsy syndrome	0.000152	0.00161	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CA4—epilepsy syndrome	0.000152	0.00161	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—POMC—epilepsy syndrome	0.000151	0.0016	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CA13—epilepsy syndrome	0.000148	0.00157	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HES1—epilepsy syndrome	0.000146	0.00155	CbGpPWpGaD
Linezolid—MAOB—Metabolism—COX3—epilepsy syndrome	0.000143	0.00151	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—CHRNA4—epilepsy syndrome	0.000142	0.0015	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—MEF2C—epilepsy syndrome	0.000141	0.0015	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—YWHAZ—epilepsy syndrome	0.000137	0.00145	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLCO1A2—epilepsy syndrome	0.000135	0.00143	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CACNA2D2—epilepsy syndrome	0.000135	0.00143	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PFKL—epilepsy syndrome	0.000135	0.00143	CbGpPWpGaD
Linezolid—MAOB—Metabolism—KCNB1—epilepsy syndrome	0.000135	0.00143	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLC6A8—epilepsy syndrome	0.000135	0.00143	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—NGF—epilepsy syndrome	0.000135	0.00143	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—NR3C1—epilepsy syndrome	0.000134	0.00142	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HTR2A—epilepsy syndrome	0.000129	0.00136	CbGpPWpGaD
Linezolid—Vision blurred—Pregabalin—epilepsy syndrome	0.000126	0.000398	CcSEcCtD
Linezolid—Rash—Midazolam—epilepsy syndrome	0.000125	0.000395	CcSEcCtD
Linezolid—Dizziness—Fosphenytoin—epilepsy syndrome	0.000125	0.000395	CcSEcCtD
Linezolid—Dermatitis—Midazolam—epilepsy syndrome	0.000125	0.000395	CcSEcCtD
Linezolid—MAOA—Neuronal System—BCHE—epilepsy syndrome	0.000125	0.00132	CbGpPWpGaD
Linezolid—Urticaria—Carbamazepine—epilepsy syndrome	0.000125	0.000394	CcSEcCtD
Linezolid—Vomiting—Levetiracetam—epilepsy syndrome	0.000124	0.000393	CcSEcCtD
Linezolid—Headache—Midazolam—epilepsy syndrome	0.000124	0.000393	CcSEcCtD
Linezolid—Pruritus—Felbamate—epilepsy syndrome	0.000124	0.000392	CcSEcCtD
Linezolid—Body temperature increased—Carbamazepine—epilepsy syndrome	0.000124	0.000392	CcSEcCtD
Linezolid—Abdominal pain—Carbamazepine—epilepsy syndrome	0.000124	0.000392	CcSEcCtD
Linezolid—Diarrhoea—Diazepam—epilepsy syndrome	0.000124	0.000392	CcSEcCtD
Linezolid—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	0.000124	0.000392	CcSEcCtD
Linezolid—MAOB—Metabolism—ATIC—epilepsy syndrome	0.000124	0.00131	CbGpPWpGaD
Linezolid—MAOB—Metabolism—UPB1—epilepsy syndrome	0.000124	0.00131	CbGpPWpGaD
Linezolid—MAOB—Metabolism—NEU1—epilepsy syndrome	0.000124	0.00131	CbGpPWpGaD
Linezolid—Rash—Levetiracetam—epilepsy syndrome	0.000123	0.00039	CcSEcCtD
Linezolid—Anaemia—Pregabalin—epilepsy syndrome	0.000123	0.00039	CcSEcCtD
Linezolid—Dermatitis—Levetiracetam—epilepsy syndrome	0.000123	0.00039	CcSEcCtD
Linezolid—Asthenia—Zonisamide—epilepsy syndrome	0.000123	0.00039	CcSEcCtD
Linezolid—Dry mouth—Valproic Acid—epilepsy syndrome	0.000123	0.000389	CcSEcCtD
Linezolid—Headache—Levetiracetam—epilepsy syndrome	0.000123	0.000388	CcSEcCtD
Linezolid—Erythema—Gabapentin—epilepsy syndrome	0.000122	0.000387	CcSEcCtD
Linezolid—Angioedema—Pregabalin—epilepsy syndrome	0.000122	0.000386	CcSEcCtD
Linezolid—Dizziness—Vigabatrin—epilepsy syndrome	0.000122	0.000385	CcSEcCtD
Linezolid—MAOA—Neuronal System—DLG4—epilepsy syndrome	0.000122	0.00129	CbGpPWpGaD
Linezolid—Pruritus—Zonisamide—epilepsy syndrome	0.000122	0.000384	CcSEcCtD
Linezolid—Flatulence—Gabapentin—epilepsy syndrome	0.000121	0.000381	CcSEcCtD
Linezolid—Anaphylactic shock—Valproic Acid—epilepsy syndrome	0.000121	0.000381	CcSEcCtD
Linezolid—Urticaria—Lamotrigine—epilepsy syndrome	0.000121	0.000381	CcSEcCtD
Linezolid—Nausea—Propofol—epilepsy syndrome	0.00012	0.00038	CcSEcCtD
Linezolid—Vomiting—Fosphenytoin—epilepsy syndrome	0.00012	0.00038	CcSEcCtD
Linezolid—Diarrhoea—Felbamate—epilepsy syndrome	0.00012	0.00038	CcSEcCtD
Linezolid—Vertigo—Pregabalin—epilepsy syndrome	0.00012	0.000379	CcSEcCtD
Linezolid—Abdominal pain—Lamotrigine—epilepsy syndrome	0.00012	0.000379	CcSEcCtD
Linezolid—Body temperature increased—Lamotrigine—epilepsy syndrome	0.00012	0.000379	CcSEcCtD
Linezolid—Dysgeusia—Gabapentin—epilepsy syndrome	0.00012	0.000379	CcSEcCtD
Linezolid—Dizziness—Diazepam—epilepsy syndrome	0.00012	0.000379	CcSEcCtD
Linezolid—Leukopenia—Pregabalin—epilepsy syndrome	0.00012	0.000378	CcSEcCtD
Linezolid—Rash—Fosphenytoin—epilepsy syndrome	0.000119	0.000377	CcSEcCtD
Linezolid—MAOB—Metabolism—HSD17B4—epilepsy syndrome	0.000119	0.00126	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIN2B—epilepsy syndrome	0.000119	0.00126	CbGpPWpGaD
Linezolid—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000119	0.000376	CcSEcCtD
Linezolid—Haemoglobin—Topiramate—epilepsy syndrome	0.000119	0.000376	CcSEcCtD
Linezolid—Asthenia—Clonazepam—epilepsy syndrome	0.000119	0.000375	CcSEcCtD
Linezolid—Headache—Fosphenytoin—epilepsy syndrome	0.000118	0.000374	CcSEcCtD
Linezolid—Haemorrhage—Topiramate—epilepsy syndrome	0.000118	0.000374	CcSEcCtD
Linezolid—Thrombocytopenia—Valproic Acid—epilepsy syndrome	0.000118	0.000373	CcSEcCtD
Linezolid—Asthenia—Phenytoin—epilepsy syndrome	0.000118	0.000373	CcSEcCtD
Linezolid—Nausea—Midazolam—epilepsy syndrome	0.000118	0.000372	CcSEcCtD
Linezolid—Hypoaesthesia—Topiramate—epilepsy syndrome	0.000118	0.000372	CcSEcCtD
Linezolid—Muscle spasms—Gabapentin—epilepsy syndrome	0.000118	0.000372	CcSEcCtD
Linezolid—MAOA—Neuronal System—PLCB1—epilepsy syndrome	0.000118	0.00125	CbGpPWpGaD
Linezolid—Diarrhoea—Zonisamide—epilepsy syndrome	0.000118	0.000371	CcSEcCtD
Linezolid—Pharyngitis—Topiramate—epilepsy syndrome	0.000117	0.000371	CcSEcCtD
Linezolid—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000117	0.000371	CcSEcCtD
Linezolid—Pruritus—Clonazepam—epilepsy syndrome	0.000117	0.00037	CcSEcCtD
Linezolid—Vomiting—Vigabatrin—epilepsy syndrome	0.000117	0.00037	CcSEcCtD
Linezolid—Skin disorder—Valproic Acid—epilepsy syndrome	0.000117	0.00037	CcSEcCtD
Linezolid—Hyperhidrosis—Valproic Acid—epilepsy syndrome	0.000117	0.000368	CcSEcCtD
Linezolid—Cough—Pregabalin—epilepsy syndrome	0.000117	0.000368	CcSEcCtD
Linezolid—Pruritus—Phenytoin—epilepsy syndrome	0.000116	0.000368	CcSEcCtD
Linezolid—Nausea—Levetiracetam—epilepsy syndrome	0.000116	0.000368	CcSEcCtD
Linezolid—Rash—Vigabatrin—epilepsy syndrome	0.000116	0.000367	CcSEcCtD
Linezolid—Dizziness—Felbamate—epilepsy syndrome	0.000116	0.000367	CcSEcCtD
Linezolid—Dermatitis—Vigabatrin—epilepsy syndrome	0.000116	0.000367	CcSEcCtD
Linezolid—Pruritus—Oxcarbazepine—epilepsy syndrome	0.000116	0.000366	CcSEcCtD
Linezolid—Convulsion—Pregabalin—epilepsy syndrome	0.000116	0.000366	CcSEcCtD
Linezolid—Vision blurred—Gabapentin—epilepsy syndrome	0.000115	0.000365	CcSEcCtD
Linezolid—Headache—Vigabatrin—epilepsy syndrome	0.000115	0.000365	CcSEcCtD
Linezolid—Hypertension—Pregabalin—epilepsy syndrome	0.000115	0.000364	CcSEcCtD
Linezolid—Vomiting—Diazepam—epilepsy syndrome	0.000115	0.000364	CcSEcCtD
Linezolid—MAOB—Metabolism—GBE1—epilepsy syndrome	0.000115	0.00122	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PPP1R3C—epilepsy syndrome	0.000115	0.00122	CbGpPWpGaD
Linezolid—Anorexia—Valproic Acid—epilepsy syndrome	0.000115	0.000363	CcSEcCtD
Linezolid—Rash—Diazepam—epilepsy syndrome	0.000114	0.000361	CcSEcCtD
Linezolid—Dermatitis—Diazepam—epilepsy syndrome	0.000114	0.000361	CcSEcCtD
Linezolid—Dizziness—Zonisamide—epilepsy syndrome	0.000114	0.000359	CcSEcCtD
Linezolid—Headache—Diazepam—epilepsy syndrome	0.000114	0.000359	CcSEcCtD
Linezolid—Diarrhoea—Clonazepam—epilepsy syndrome	0.000113	0.000358	CcSEcCtD
Linezolid—Anaemia—Gabapentin—epilepsy syndrome	0.000113	0.000358	CcSEcCtD
Linezolid—Asthenia—Carbamazepine—epilepsy syndrome	0.000113	0.000356	CcSEcCtD
Linezolid—Diarrhoea—Phenytoin—epilepsy syndrome	0.000113	0.000356	CcSEcCtD
Linezolid—Nausea—Fosphenytoin—epilepsy syndrome	0.000112	0.000355	CcSEcCtD
Linezolid—MAOA—Metabolism—ADK—epilepsy syndrome	0.000112	0.00119	CbGpPWpGaD
Linezolid—MAOA—Metabolism—FAR1—epilepsy syndrome	0.000112	0.00119	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PDXK—epilepsy syndrome	0.000112	0.00119	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CERS1—epilepsy syndrome	0.000112	0.00119	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GLUD1—epilepsy syndrome	0.000112	0.00119	CbGpPWpGaD
Linezolid—MAOA—Metabolism—L2HGDH—epilepsy syndrome	0.000112	0.00119	CbGpPWpGaD
Linezolid—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000112	0.000354	CcSEcCtD
Linezolid—Erythema multiforme—Topiramate—epilepsy syndrome	0.000112	0.000354	CcSEcCtD
Linezolid—Angioedema—Gabapentin—epilepsy syndrome	0.000112	0.000354	CcSEcCtD
Linezolid—Vomiting—Felbamate—epilepsy syndrome	0.000112	0.000353	CcSEcCtD
Linezolid—Dry mouth—Pregabalin—epilepsy syndrome	0.000111	0.000351	CcSEcCtD
Linezolid—Pruritus—Carbamazepine—epilepsy syndrome	0.000111	0.000351	CcSEcCtD
Linezolid—Rash—Felbamate—epilepsy syndrome	0.000111	0.00035	CcSEcCtD
Linezolid—Dermatitis—Felbamate—epilepsy syndrome	0.000111	0.000349	CcSEcCtD
Linezolid—Tinnitus—Topiramate—epilepsy syndrome	0.00011	0.000349	CcSEcCtD
Linezolid—Vertigo—Gabapentin—epilepsy syndrome	0.00011	0.000348	CcSEcCtD
Linezolid—Headache—Felbamate—epilepsy syndrome	0.00011	0.000347	CcSEcCtD
Linezolid—Leukopenia—Gabapentin—epilepsy syndrome	0.00011	0.000346	CcSEcCtD
Linezolid—Dizziness—Clonazepam—epilepsy syndrome	0.000109	0.000346	CcSEcCtD
Linezolid—Nausea—Vigabatrin—epilepsy syndrome	0.000109	0.000346	CcSEcCtD
Linezolid—Vomiting—Zonisamide—epilepsy syndrome	0.000109	0.000345	CcSEcCtD
Linezolid—Insomnia—Valproic Acid—epilepsy syndrome	0.000109	0.000345	CcSEcCtD
Linezolid—Anaphylactic shock—Pregabalin—epilepsy syndrome	0.000109	0.000344	CcSEcCtD
Linezolid—Asthenia—Lamotrigine—epilepsy syndrome	0.000109	0.000344	CcSEcCtD
Linezolid—Dizziness—Phenytoin—epilepsy syndrome	0.000109	0.000344	CcSEcCtD
Linezolid—Rash—Zonisamide—epilepsy syndrome	0.000108	0.000342	CcSEcCtD
Linezolid—Paraesthesia—Valproic Acid—epilepsy syndrome	0.000108	0.000342	CcSEcCtD
Linezolid—Dermatitis—Zonisamide—epilepsy syndrome	0.000108	0.000342	CcSEcCtD
Linezolid—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000108	0.000342	CcSEcCtD
Linezolid—MAOB—Metabolism—ASAH1—epilepsy syndrome	0.000108	0.00115	CbGpPWpGaD
Linezolid—Nausea—Diazepam—epilepsy syndrome	0.000108	0.00034	CcSEcCtD
Linezolid—Headache—Zonisamide—epilepsy syndrome	0.000108	0.00034	CcSEcCtD
Linezolid—Dyspnoea—Valproic Acid—epilepsy syndrome	0.000107	0.00034	CcSEcCtD
Linezolid—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000107	0.000339	CcSEcCtD
Linezolid—Pruritus—Lamotrigine—epilepsy syndrome	0.000107	0.000339	CcSEcCtD
Linezolid—Somnolence—Valproic Acid—epilepsy syndrome	0.000107	0.000339	CcSEcCtD
Linezolid—Cough—Gabapentin—epilepsy syndrome	0.000107	0.000338	CcSEcCtD
Linezolid—Thrombocytopenia—Pregabalin—epilepsy syndrome	0.000107	0.000337	CcSEcCtD
Linezolid—Chills—Topiramate—epilepsy syndrome	0.000106	0.000336	CcSEcCtD
Linezolid—Dyspepsia—Valproic Acid—epilepsy syndrome	0.000106	0.000335	CcSEcCtD
Linezolid—Convulsion—Gabapentin—epilepsy syndrome	0.000106	0.000335	CcSEcCtD
Linezolid—Skin disorder—Pregabalin—epilepsy syndrome	0.000106	0.000335	CcSEcCtD
Linezolid—Hypertension—Gabapentin—epilepsy syndrome	0.000106	0.000334	CcSEcCtD
Linezolid—Hyperhidrosis—Pregabalin—epilepsy syndrome	0.000105	0.000333	CcSEcCtD
Linezolid—Vomiting—Clonazepam—epilepsy syndrome	0.000105	0.000333	CcSEcCtD
Linezolid—MAOB—Metabolism—STXBP1—epilepsy syndrome	0.000105	0.00111	CbGpPWpGaD
Linezolid—Decreased appetite—Valproic Acid—epilepsy syndrome	0.000105	0.000331	CcSEcCtD
Linezolid—Vomiting—Phenytoin—epilepsy syndrome	0.000105	0.00033	CcSEcCtD
Linezolid—Rash—Clonazepam—epilepsy syndrome	0.000104	0.00033	CcSEcCtD
Linezolid—Dermatitis—Clonazepam—epilepsy syndrome	0.000104	0.00033	CcSEcCtD
Linezolid—Nausea—Felbamate—epilepsy syndrome	0.000104	0.000329	CcSEcCtD
Linezolid—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.000104	0.000329	CcSEcCtD
Linezolid—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000104	0.000329	CcSEcCtD
Linezolid—Fatigue—Valproic Acid—epilepsy syndrome	0.000104	0.000328	CcSEcCtD
Linezolid—Anorexia—Pregabalin—epilepsy syndrome	0.000104	0.000328	CcSEcCtD
Linezolid—Dizziness—Carbamazepine—epilepsy syndrome	0.000104	0.000328	CcSEcCtD
Linezolid—Diarrhoea—Lamotrigine—epilepsy syndrome	0.000104	0.000328	CcSEcCtD
Linezolid—Headache—Clonazepam—epilepsy syndrome	0.000104	0.000328	CcSEcCtD
Linezolid—Rash—Phenytoin—epilepsy syndrome	0.000104	0.000328	CcSEcCtD
Linezolid—Dermatitis—Phenytoin—epilepsy syndrome	0.000104	0.000327	CcSEcCtD
Linezolid—Rash—Oxcarbazepine—epilepsy syndrome	0.000103	0.000326	CcSEcCtD
Linezolid—Constipation—Valproic Acid—epilepsy syndrome	0.000103	0.000326	CcSEcCtD
Linezolid—Pain—Valproic Acid—epilepsy syndrome	0.000103	0.000326	CcSEcCtD
Linezolid—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000103	0.000326	CcSEcCtD
Linezolid—Headache—Phenytoin—epilepsy syndrome	0.000103	0.000326	CcSEcCtD
Linezolid—Erythema—Topiramate—epilepsy syndrome	0.000103	0.000326	CcSEcCtD
Linezolid—MAOB—Metabolism—NT5E—epilepsy syndrome	0.000103	0.00109	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ALAD—epilepsy syndrome	0.000103	0.00109	CbGpPWpGaD
Linezolid—Headache—Oxcarbazepine—epilepsy syndrome	0.000102	0.000324	CcSEcCtD
Linezolid—MAOA—Metabolism—GAMT—epilepsy syndrome	0.000102	0.00109	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PNPO—epilepsy syndrome	0.000102	0.00109	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NHLRC1—epilepsy syndrome	0.000102	0.00109	CbGpPWpGaD
Linezolid—MAOA—Metabolism—EPM2A—epilepsy syndrome	0.000102	0.00109	CbGpPWpGaD
Linezolid—Nausea—Zonisamide—epilepsy syndrome	0.000102	0.000322	CcSEcCtD
Linezolid—Dry mouth—Gabapentin—epilepsy syndrome	0.000102	0.000322	CcSEcCtD
Linezolid—Flatulence—Topiramate—epilepsy syndrome	0.000102	0.000321	CcSEcCtD
Linezolid—Dysgeusia—Topiramate—epilepsy syndrome	0.000101	0.000319	CcSEcCtD
Linezolid—Dizziness—Lamotrigine—epilepsy syndrome	0.0001	0.000317	CcSEcCtD
Linezolid—Anaphylactic shock—Gabapentin—epilepsy syndrome	9.99e-05	0.000316	CcSEcCtD
Linezolid—Vomiting—Carbamazepine—epilepsy syndrome	9.98e-05	0.000315	CcSEcCtD
Linezolid—Muscle spasms—Topiramate—epilepsy syndrome	9.91e-05	0.000313	CcSEcCtD
Linezolid—Rash—Carbamazepine—epilepsy syndrome	9.9e-05	0.000313	CcSEcCtD
Linezolid—Dermatitis—Carbamazepine—epilepsy syndrome	9.89e-05	0.000313	CcSEcCtD
Linezolid—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	9.86e-05	0.000312	CcSEcCtD
Linezolid—Insomnia—Pregabalin—epilepsy syndrome	9.86e-05	0.000312	CcSEcCtD
Linezolid—Nausea—Clonazepam—epilepsy syndrome	9.83e-05	0.000311	CcSEcCtD
Linezolid—Headache—Carbamazepine—epilepsy syndrome	9.83e-05	0.000311	CcSEcCtD
Linezolid—Paraesthesia—Pregabalin—epilepsy syndrome	9.79e-05	0.000309	CcSEcCtD
Linezolid—Thrombocytopenia—Gabapentin—epilepsy syndrome	9.79e-05	0.000309	CcSEcCtD
Linezolid—MAOB—Metabolism—ALDH7A1—epilepsy syndrome	9.78e-05	0.00104	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CACNA1A—epilepsy syndrome	9.78e-05	0.00104	CbGpPWpGaD
Linezolid—Nausea—Phenytoin—epilepsy syndrome	9.77e-05	0.000309	CcSEcCtD
Linezolid—Dyspnoea—Pregabalin—epilepsy syndrome	9.72e-05	0.000307	CcSEcCtD
Linezolid—Nausea—Oxcarbazepine—epilepsy syndrome	9.72e-05	0.000307	CcSEcCtD
Linezolid—Vision blurred—Topiramate—epilepsy syndrome	9.71e-05	0.000307	CcSEcCtD
Linezolid—Skin disorder—Gabapentin—epilepsy syndrome	9.71e-05	0.000307	CcSEcCtD
Linezolid—Somnolence—Pregabalin—epilepsy syndrome	9.69e-05	0.000306	CcSEcCtD
Linezolid—Hyperhidrosis—Gabapentin—epilepsy syndrome	9.66e-05	0.000305	CcSEcCtD
Linezolid—Vomiting—Lamotrigine—epilepsy syndrome	9.65e-05	0.000305	CcSEcCtD
Linezolid—Urticaria—Valproic Acid—epilepsy syndrome	9.58e-05	0.000303	CcSEcCtD
Linezolid—MAOB—Metabolism—ST3GAL3—epilepsy syndrome	9.57e-05	0.00101	CbGpPWpGaD
Linezolid—Rash—Lamotrigine—epilepsy syndrome	9.57e-05	0.000302	CcSEcCtD
Linezolid—Dermatitis—Lamotrigine—epilepsy syndrome	9.56e-05	0.000302	CcSEcCtD
Linezolid—Body temperature increased—Valproic Acid—epilepsy syndrome	9.53e-05	0.000301	CcSEcCtD
Linezolid—Abdominal pain—Valproic Acid—epilepsy syndrome	9.53e-05	0.000301	CcSEcCtD
Linezolid—Anorexia—Gabapentin—epilepsy syndrome	9.53e-05	0.000301	CcSEcCtD
Linezolid—MAOA—Metabolism—CA4—epilepsy syndrome	9.52e-05	0.00101	CbGpPWpGaD
Linezolid—MAOA—Metabolism—QDPR—epilepsy syndrome	9.52e-05	0.00101	CbGpPWpGaD
Linezolid—Anaemia—Topiramate—epilepsy syndrome	9.52e-05	0.000301	CcSEcCtD
Linezolid—Headache—Lamotrigine—epilepsy syndrome	9.5e-05	0.0003	CcSEcCtD
Linezolid—MAOA—Biological oxidations—POMC—epilepsy syndrome	9.5e-05	0.00101	CbGpPWpGaD
Linezolid—Decreased appetite—Pregabalin—epilepsy syndrome	9.47e-05	0.000299	CcSEcCtD
Linezolid—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	9.41e-05	0.000297	CcSEcCtD
Linezolid—Fatigue—Pregabalin—epilepsy syndrome	9.4e-05	0.000297	CcSEcCtD
Linezolid—MAOB—Metabolism—ADSL—epilepsy syndrome	9.38e-05	0.000993	CbGpPWpGaD
Linezolid—Nausea—Carbamazepine—epilepsy syndrome	9.32e-05	0.000295	CcSEcCtD
Linezolid—Pain—Pregabalin—epilepsy syndrome	9.32e-05	0.000295	CcSEcCtD
Linezolid—Constipation—Pregabalin—epilepsy syndrome	9.32e-05	0.000295	CcSEcCtD
Linezolid—Vertigo—Topiramate—epilepsy syndrome	9.26e-05	0.000293	CcSEcCtD
Linezolid—MAOA—Transmission across Chemical Synapses—PRKCB—epilepsy syndrome	9.24e-05	0.000979	CbGpPWpGaD
Linezolid—Leukopenia—Topiramate—epilepsy syndrome	9.22e-05	0.000291	CcSEcCtD
Linezolid—MAOB—Metabolism—GLUL—epilepsy syndrome	9.2e-05	0.000974	CbGpPWpGaD
Linezolid—Insomnia—Gabapentin—epilepsy syndrome	9.04e-05	0.000286	CcSEcCtD
Linezolid—MAOB—Metabolism—CACNA1D—epilepsy syndrome	9.03e-05	0.000956	CbGpPWpGaD
Linezolid—Nausea—Lamotrigine—epilepsy syndrome	9.01e-05	0.000285	CcSEcCtD
Linezolid—Cough—Topiramate—epilepsy syndrome	8.99e-05	0.000284	CcSEcCtD
Linezolid—Paraesthesia—Gabapentin—epilepsy syndrome	8.97e-05	0.000284	CcSEcCtD
Linezolid—MAOA—Metabolism—COX3—epilepsy syndrome	8.96e-05	0.000949	CbGpPWpGaD
Linezolid—Convulsion—Topiramate—epilepsy syndrome	8.93e-05	0.000282	CcSEcCtD
Linezolid—Gastrointestinal pain—Pregabalin—epilepsy syndrome	8.91e-05	0.000282	CcSEcCtD
Linezolid—Dyspnoea—Gabapentin—epilepsy syndrome	8.91e-05	0.000282	CcSEcCtD
Linezolid—Hypertension—Topiramate—epilepsy syndrome	8.89e-05	0.000281	CcSEcCtD
Linezolid—Somnolence—Gabapentin—epilepsy syndrome	8.88e-05	0.000281	CcSEcCtD
Linezolid—Dyspepsia—Gabapentin—epilepsy syndrome	8.8e-05	0.000278	CcSEcCtD
Linezolid—Decreased appetite—Gabapentin—epilepsy syndrome	8.69e-05	0.000275	CcSEcCtD
Linezolid—Urticaria—Pregabalin—epilepsy syndrome	8.66e-05	0.000274	CcSEcCtD
Linezolid—Asthenia—Valproic Acid—epilepsy syndrome	8.65e-05	0.000273	CcSEcCtD
Linezolid—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	8.63e-05	0.000273	CcSEcCtD
Linezolid—Fatigue—Gabapentin—epilepsy syndrome	8.62e-05	0.000272	CcSEcCtD
Linezolid—Abdominal pain—Pregabalin—epilepsy syndrome	8.62e-05	0.000272	CcSEcCtD
Linezolid—Body temperature increased—Pregabalin—epilepsy syndrome	8.62e-05	0.000272	CcSEcCtD
Linezolid—Dry mouth—Topiramate—epilepsy syndrome	8.58e-05	0.000271	CcSEcCtD
Linezolid—Constipation—Gabapentin—epilepsy syndrome	8.55e-05	0.00027	CcSEcCtD
Linezolid—Pain—Gabapentin—epilepsy syndrome	8.55e-05	0.00027	CcSEcCtD
Linezolid—Pruritus—Valproic Acid—epilepsy syndrome	8.53e-05	0.00027	CcSEcCtD
Linezolid—MAOA—Metabolism—SLCO1A2—epilepsy syndrome	8.49e-05	0.000899	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CACNA2D2—epilepsy syndrome	8.49e-05	0.000899	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PFKL—epilepsy syndrome	8.49e-05	0.000899	CbGpPWpGaD
Linezolid—MAOA—Metabolism—KCNB1—epilepsy syndrome	8.49e-05	0.000899	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SLC6A8—epilepsy syndrome	8.49e-05	0.000899	CbGpPWpGaD
Linezolid—MAOB—Metabolism—TXNRD1—epilepsy syndrome	8.44e-05	0.000894	CbGpPWpGaD
Linezolid—Diarrhoea—Valproic Acid—epilepsy syndrome	8.25e-05	0.000261	CcSEcCtD
Linezolid—Thrombocytopenia—Topiramate—epilepsy syndrome	8.23e-05	0.00026	CcSEcCtD
Linezolid—MAOB—Metabolism—AQP1—epilepsy syndrome	8.2e-05	0.000868	CbGpPWpGaD
Linezolid—Gastrointestinal pain—Gabapentin—epilepsy syndrome	8.17e-05	0.000258	CcSEcCtD
Linezolid—Skin disorder—Topiramate—epilepsy syndrome	8.17e-05	0.000258	CcSEcCtD
Linezolid—Hyperhidrosis—Topiramate—epilepsy syndrome	8.13e-05	0.000257	CcSEcCtD
Linezolid—Anorexia—Topiramate—epilepsy syndrome	8.01e-05	0.000253	CcSEcCtD
Linezolid—Dizziness—Valproic Acid—epilepsy syndrome	7.97e-05	0.000252	CcSEcCtD
Linezolid—Urticaria—Gabapentin—epilepsy syndrome	7.94e-05	0.000251	CcSEcCtD
Linezolid—Abdominal pain—Gabapentin—epilepsy syndrome	7.9e-05	0.00025	CcSEcCtD
Linezolid—Body temperature increased—Gabapentin—epilepsy syndrome	7.9e-05	0.00025	CcSEcCtD
Linezolid—Asthenia—Pregabalin—epilepsy syndrome	7.82e-05	0.000247	CcSEcCtD
Linezolid—MAOA—Metabolism—ATIC—epilepsy syndrome	7.76e-05	0.000822	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NEU1—epilepsy syndrome	7.76e-05	0.000822	CbGpPWpGaD
Linezolid—MAOA—Metabolism—UPB1—epilepsy syndrome	7.76e-05	0.000822	CbGpPWpGaD
Linezolid—Pruritus—Pregabalin—epilepsy syndrome	7.71e-05	0.000244	CcSEcCtD
Linezolid—Vomiting—Valproic Acid—epilepsy syndrome	7.67e-05	0.000242	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL1B—epilepsy syndrome	7.62e-05	0.000807	CbGpPWpGaD
Linezolid—Insomnia—Topiramate—epilepsy syndrome	7.6e-05	0.00024	CcSEcCtD
Linezolid—Rash—Valproic Acid—epilepsy syndrome	7.6e-05	0.00024	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—CASP3—epilepsy syndrome	7.6e-05	0.000805	CbGpPWpGaD
Linezolid—Dermatitis—Valproic Acid—epilepsy syndrome	7.59e-05	0.00024	CcSEcCtD
Linezolid—Headache—Valproic Acid—epilepsy syndrome	7.55e-05	0.000239	CcSEcCtD
Linezolid—Paraesthesia—Topiramate—epilepsy syndrome	7.55e-05	0.000239	CcSEcCtD
Linezolid—Dyspnoea—Topiramate—epilepsy syndrome	7.5e-05	0.000237	CcSEcCtD
Linezolid—Somnolence—Topiramate—epilepsy syndrome	7.47e-05	0.000236	CcSEcCtD
Linezolid—MAOA—Metabolism—HSD17B4—epilepsy syndrome	7.47e-05	0.000792	CbGpPWpGaD
Linezolid—Diarrhoea—Pregabalin—epilepsy syndrome	7.46e-05	0.000236	CcSEcCtD
Linezolid—MAOB—Metabolism—CHRM3—epilepsy syndrome	7.41e-05	0.000785	CbGpPWpGaD
Linezolid—MAOB—Metabolism—KCNJ11—epilepsy syndrome	7.41e-05	0.000785	CbGpPWpGaD
Linezolid—Dyspepsia—Topiramate—epilepsy syndrome	7.4e-05	0.000234	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—JUN—epilepsy syndrome	7.38e-05	0.000782	CbGpPWpGaD
Linezolid—Decreased appetite—Topiramate—epilepsy syndrome	7.31e-05	0.000231	CcSEcCtD
Linezolid—Gastrointestinal disorder—Topiramate—epilepsy syndrome	7.26e-05	0.000229	CcSEcCtD
Linezolid—Fatigue—Topiramate—epilepsy syndrome	7.25e-05	0.000229	CcSEcCtD
Linezolid—MAOA—Metabolism—PPP1R3C—epilepsy syndrome	7.22e-05	0.000765	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GBE1—epilepsy syndrome	7.22e-05	0.000765	CbGpPWpGaD
Linezolid—Dizziness—Pregabalin—epilepsy syndrome	7.21e-05	0.000228	CcSEcCtD
Linezolid—Constipation—Topiramate—epilepsy syndrome	7.19e-05	0.000227	CcSEcCtD
Linezolid—Pain—Topiramate—epilepsy syndrome	7.19e-05	0.000227	CcSEcCtD
Linezolid—Asthenia—Gabapentin—epilepsy syndrome	7.17e-05	0.000227	CcSEcCtD
Linezolid—Nausea—Valproic Acid—epilepsy syndrome	7.16e-05	0.000226	CcSEcCtD
Linezolid—MAOA—Neuronal System—PRKCB—epilepsy syndrome	7.08e-05	0.00075	CbGpPWpGaD
Linezolid—Pruritus—Gabapentin—epilepsy syndrome	7.07e-05	0.000223	CcSEcCtD
Linezolid—Vomiting—Pregabalin—epilepsy syndrome	6.93e-05	0.000219	CcSEcCtD
Linezolid—Gastrointestinal pain—Topiramate—epilepsy syndrome	6.88e-05	0.000217	CcSEcCtD
Linezolid—Rash—Pregabalin—epilepsy syndrome	6.87e-05	0.000217	CcSEcCtD
Linezolid—Dermatitis—Pregabalin—epilepsy syndrome	6.87e-05	0.000217	CcSEcCtD
Linezolid—Diarrhoea—Gabapentin—epilepsy syndrome	6.84e-05	0.000216	CcSEcCtD
Linezolid—Headache—Pregabalin—epilepsy syndrome	6.83e-05	0.000216	CcSEcCtD
Linezolid—MAOA—Metabolism—ASAH1—epilepsy syndrome	6.79e-05	0.000719	CbGpPWpGaD
Linezolid—Urticaria—Topiramate—epilepsy syndrome	6.68e-05	0.000211	CcSEcCtD
Linezolid—Abdominal pain—Topiramate—epilepsy syndrome	6.65e-05	0.00021	CcSEcCtD
Linezolid—Body temperature increased—Topiramate—epilepsy syndrome	6.65e-05	0.00021	CcSEcCtD
Linezolid—Dizziness—Gabapentin—epilepsy syndrome	6.61e-05	0.000209	CcSEcCtD
Linezolid—MAOA—Metabolism—STXBP1—epilepsy syndrome	6.6e-05	0.000699	CbGpPWpGaD
Linezolid—Nausea—Pregabalin—epilepsy syndrome	6.47e-05	0.000205	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—VEGFA—epilepsy syndrome	6.45e-05	0.000683	CbGpPWpGaD
Linezolid—MAOA—Metabolism—NT5E—epilepsy syndrome	6.43e-05	0.000681	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ALAD—epilepsy syndrome	6.43e-05	0.000681	CbGpPWpGaD
Linezolid—Vomiting—Gabapentin—epilepsy syndrome	6.35e-05	0.000201	CcSEcCtD
Linezolid—Rash—Gabapentin—epilepsy syndrome	6.3e-05	0.000199	CcSEcCtD
Linezolid—Dermatitis—Gabapentin—epilepsy syndrome	6.3e-05	0.000199	CcSEcCtD
Linezolid—Headache—Gabapentin—epilepsy syndrome	6.26e-05	0.000198	CcSEcCtD
Linezolid—MAOA—Metabolism—ALDH7A1—epilepsy syndrome	6.14e-05	0.00065	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CACNA1A—epilepsy syndrome	6.14e-05	0.00065	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ABCG2—epilepsy syndrome	6.04e-05	0.00064	CbGpPWpGaD
Linezolid—Asthenia—Topiramate—epilepsy syndrome	6.03e-05	0.000191	CcSEcCtD
Linezolid—MAOA—Metabolism—ST3GAL3—epilepsy syndrome	6.01e-05	0.000636	CbGpPWpGaD
Linezolid—Pruritus—Topiramate—epilepsy syndrome	5.95e-05	0.000188	CcSEcCtD
Linezolid—Nausea—Gabapentin—epilepsy syndrome	5.94e-05	0.000188	CcSEcCtD
Linezolid—MAOB—Metabolism—CYP2C19—epilepsy syndrome	5.89e-05	0.000624	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ADSL—epilepsy syndrome	5.88e-05	0.000623	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP11A1—epilepsy syndrome	5.85e-05	0.00062	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GLUL—epilepsy syndrome	5.77e-05	0.000611	CbGpPWpGaD
Linezolid—Diarrhoea—Topiramate—epilepsy syndrome	5.75e-05	0.000182	CcSEcCtD
Linezolid—MAOA—Metabolism—CACNA1D—epilepsy syndrome	5.66e-05	0.0006	CbGpPWpGaD
Linezolid—Dizziness—Topiramate—epilepsy syndrome	5.56e-05	0.000176	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—TNF—epilepsy syndrome	5.53e-05	0.000586	CbGpPWpGaD
Linezolid—Vomiting—Topiramate—epilepsy syndrome	5.35e-05	0.000169	CcSEcCtD
Linezolid—Rash—Topiramate—epilepsy syndrome	5.3e-05	0.000168	CcSEcCtD
Linezolid—MAOA—Metabolism—TXNRD1—epilepsy syndrome	5.3e-05	0.000561	CbGpPWpGaD
Linezolid—Dermatitis—Topiramate—epilepsy syndrome	5.3e-05	0.000167	CcSEcCtD
Linezolid—MAOB—Metabolism—CYP2D6—epilepsy syndrome	5.28e-05	0.000559	CbGpPWpGaD
Linezolid—Headache—Topiramate—epilepsy syndrome	5.27e-05	0.000166	CcSEcCtD
Linezolid—MAOA—Metabolism—AQP1—epilepsy syndrome	5.14e-05	0.000545	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ADRA2A—epilepsy syndrome	5.03e-05	0.000533	CbGpPWpGaD
Linezolid—MAOB—Metabolism—BCHE—epilepsy syndrome	5.01e-05	0.00053	CbGpPWpGaD
Linezolid—Nausea—Topiramate—epilepsy syndrome	4.99e-05	0.000158	CcSEcCtD
Linezolid—MAOB—Metabolism—SLC2A1—epilepsy syndrome	4.78e-05	0.000506	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PLCB1—epilepsy syndrome	4.72e-05	0.0005	CbGpPWpGaD
Linezolid—MAOB—Metabolism—TH—epilepsy syndrome	4.71e-05	0.000499	CbGpPWpGaD
Linezolid—MAOA—Metabolism—KCNJ11—epilepsy syndrome	4.65e-05	0.000493	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CHRM3—epilepsy syndrome	4.65e-05	0.000493	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HMOX1—epilepsy syndrome	3.93e-05	0.000416	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CAT—epilepsy syndrome	3.88e-05	0.000411	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ABCG2—epilepsy syndrome	3.79e-05	0.000402	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ABCB1—epilepsy syndrome	3.77e-05	0.000399	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP2C19—epilepsy syndrome	3.7e-05	0.000391	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP11A1—epilepsy syndrome	3.67e-05	0.000389	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GPX1—epilepsy syndrome	3.51e-05	0.000371	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP2D6—epilepsy syndrome	3.31e-05	0.000351	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ADRA2A—epilepsy syndrome	3.16e-05	0.000334	CbGpPWpGaD
Linezolid—MAOA—Metabolism—BCHE—epilepsy syndrome	3.14e-05	0.000333	CbGpPWpGaD
Linezolid—MAOB—Metabolism—AGT—epilepsy syndrome	3.07e-05	0.000326	CbGpPWpGaD
Linezolid—MAOB—Metabolism—APOE—epilepsy syndrome	3.01e-05	0.000319	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SLC2A1—epilepsy syndrome	3e-05	0.000317	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PLCB1—epilepsy syndrome	2.96e-05	0.000314	CbGpPWpGaD
Linezolid—MAOA—Metabolism—TH—epilepsy syndrome	2.95e-05	0.000313	CbGpPWpGaD
Linezolid—MAOB—Metabolism—POMC—epilepsy syndrome	2.59e-05	0.000274	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HMOX1—epilepsy syndrome	2.47e-05	0.000261	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CAT—epilepsy syndrome	2.43e-05	0.000258	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ABCB1—epilepsy syndrome	2.37e-05	0.000251	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ALB—epilepsy syndrome	2.36e-05	0.00025	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GPX1—epilepsy syndrome	2.2e-05	0.000233	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTGS2—epilepsy syndrome	2.06e-05	0.000219	CbGpPWpGaD
Linezolid—MAOA—Metabolism—AGT—epilepsy syndrome	1.93e-05	0.000204	CbGpPWpGaD
Linezolid—MAOA—Metabolism—APOE—epilepsy syndrome	1.89e-05	0.0002	CbGpPWpGaD
Linezolid—MAOA—Metabolism—POMC—epilepsy syndrome	1.62e-05	0.000172	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ALB—epilepsy syndrome	1.48e-05	0.000157	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTGS2—epilepsy syndrome	1.3e-05	0.000137	CbGpPWpGaD
Linezolid—MAOB—Metabolism—AKT1—epilepsy syndrome	1.04e-05	0.00011	CbGpPWpGaD
Linezolid—MAOA—Metabolism—AKT1—epilepsy syndrome	6.51e-06	6.89e-05	CbGpPWpGaD
